GSK
GSK and Roche get EU breast cancer indication
August 15, 2013Sales and Marketing GSK, Herceptin, Roche, Tyverb, Xeloda, breast cancer
The European Commission has granted a new indication for the use of GSK’s breast cancer drug Tyverb in combination with …
HIV pill Tivicay gains FDA approval
August 14, 2013Sales and Marketing FDA, GSK, Tivicay, ViiV
ViiV and partner GlaxoSmithKline’s new HIV drug Tivicay has been shown the FDA’s green light for distribution in the US. …
Bribery ‘routine’ for pharma in China
August 13, 2013Sales and Marketing BBC, China, GSK, Sanofi, bribery, drug reps
AllTrials campaign releases manifesto
August 9, 2013Medical Communications, Research and Development, Sales and Marketing Bad pharma, GSK, Goldacre, NICE, transparency
The UK clinical trial transparency initiative AllTrials has released its first detailed manifesto as it looks to ramp up pressure …
GSK banks on bioelectronics with new fund
August 9, 2013Medical Communications, Research and Development, Sales and Marketing Bioelectronics, COPD, GSK, asthma, diabetes
GSK has established a $50 million venture capital fund to invest in the emerging field of bioelectronics. Described as one …
GSK seeks licence extensions
August 8, 2013Sales and Marketing Cervarix, EMA, GSK, Votrient
GlaxoSmithKline is seeking to extend the licences of two of its brands, Cervarix and Votrient, in a bid to extend …
FDA makes GSK wait
August 6, 2013Sales and Marketing FDA, GSK, albiglutide, diabetes
The FDA is making GlaxoSmithKline wait for a verdict on the manufacturer’s investigational type 2 diabetes treatment albiglutide, extending its …
GSK loses Tyverb patent
August 6, 2013Sales and Marketing Cancer, GSK, GlaxoSmithKline, Tyverb
GlaxoSmithKline has received a knockback from authorities in India, who have revoked the patent on its breast cancer drug Tyverb. …
Actions in China ‘shameful’ says GSK boss
July 25, 2013Medical Communications, Sales and Marketing China, GSK, Witty, bribery
GlaxoSmithKline has admitted that allegations of corruption at its China business are ‘shameful’ and will seek out its cause. Speaking …
Benlysta once again rejected by NICE
July 25, 2013Sales and Marketing Benlysta, GSK, NHS, NICE
NICE has opened a second public consultation for GSK’s lupus drug Benlysta after the Institute has again rejected the medicine …
GSK sales up – impact of China allegations to follow
July 24, 2013Sales and Marketing GSK, Q2, Seretide, Seroxat, Witty, bribery, transparency
GlaxoSmithKline has reported a modest rise in sales but the fallout from China’s bribery probe dominates the firm’s release of …
AstraZeneca staff questioned in China
July 23, 2013Medical Communications, Sales and Marketing AstraZeneca, China, GSK, bribery
AstraZeneca says it has no details on the reasons why three of its employees in China have been questioned by …
Latest content
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership
